TORCH and UPLIFT: What has been learned from the COPD "mega- trials"?

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 6, Issue 1, 2009, Pages 1-3

  Niewoehner, Dennis E ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

COPD; Salmeterol fluticasone propionate; Tiotropium; TORCH; UPLIFT

Indexed keywords

FLUTICASONE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW;

ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES;

EID: 61649107441     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550902723984     Document Type: Review

References (13)

1. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: A systematic review for a clinical practice guideline. Ann Intern Med 2007; 147:639-663.
2. Calverley PMA, Anderson JA, Delli B, Ferguson GT, Jenkings C, Jones PW, Yates JC, Vestbo, J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
3. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjogee SM, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-1554.
4. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536-542.
5. Sin DD, Wu L, Anderson, JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60:992-997.
6. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20:819-825.
7. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18:75-81.
8. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins C, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PMA. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Results from the TORCH Study. Am J Respir Crit Care Med 2008; 178:332-338.
9. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003; 124:1350-1356.
10. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: Anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21:1011-1019.
11. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD. A meta-analysis. Chest 2004; 125:2309-2321.
12. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008; 300:1439-1450.
13. La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med 2007; 356:2211-2212.